To our best knowledge, there are no clinical trial studies ongoing, which evaluate the safety and efficacy of HSP90 or BCL6 inhibitors in patients with newly diagnosed or relapsed/refractory DLBCL. Here, BCL6 is linked to diffuse large B-cell lymphoma.